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OBJECTIVES We sought to test the hypothesis that plasma volume (PV) expansion in heart transplant
recipients (HTRs) is caused by failure to reflexively suppress the renin-angiotensin-
aldosterone (RAA) axis.
BACKGROUND Extracellular fluid volume expansion occurs in clinically stable HTRs who become hyper-
tensive. We have previously demonstrated that the RAA axis is not reflexively suppressed by
a hypervolemic stimulus in HTRs.
METHODS Plasma volume and fluid regulatory hormones were measured in eight HTRs (57 6 6 years
old) both before and after treatment with captopril (225 mg/day). Antihypertensive and
diuretic agents were discontinued 10 days before. The HTRs were admitted to the Clinical
Research Center (CRC), and, after three days of a constant diet containing 87 mEq/day of
Na1, PV was measured by using the modified Evans blue dye dilution technique. After
approximately four months (16 6 5 weeks), the same HTRs again discontinued all
antihypertensive and diuretic agents; they were progressed to a captopril dose of 75 mg three
times per day over 14 days, and the CRC protocol was repeated.
RESULTS Captopril pharmacologically suppressed (p , 0.05) supine rest levels of angiotensin II
(265%) and aldosterone (275%). The reductions in vasopressin and atrial natriuretic peptide
levels after captopril did not reach statistical significance. The PV, normalized for body
weight (ml/kg), was significantly reduced by 12% when the HTRs received captopril.
CONCLUSIONS Extracellular fluid volume is expanded (12%) in clinically stable HTRs who become
hypertensive. Pharmacologic suppression of the RAA axis with high-dose captopril
(225 mg/day) returned HTRs to a normovolemic state. These findings indicate that fluid
retention is partly engendered by a failure to reflexively suppress the RAA axis when HTRs
become hypervolemic. (J Am Coll Cardiol 2000;36:487–92) © 2000 by the American
College of Cardiology
Extracellular fluid volume expansion is well documented in
clinically stable heart transplant recipients (HTRs) who
become hypertensive (1–3). The mechanism of fluid reten-
tion in HTRs is not completely understood but has previ-
ously been attributed to the effects of the immunosuppres-
sant agent cyclosporine. Indeed, both cyclosporine-
mediated sympathoexcitation and nephrotoxicity could alter
salt and water handling in these patients (4,5). Recent
evidence suggests, however, that long-term fluid retention
in HTRs may extend beyond cyclosporine-related mecha-
nisms (1–3,6–8).
An alternative hypothesis is that denervation of cardiac
volume receptors is the mechanism responsible for fluid
retention in HTRs. In HTRs, arginine vasopressin (AVP)
levels are not suppressed during the supine posture (6);
plasma renin activity is not suppressed by water immersion
(7); and abrupt volume expansion with isotonic saline
infusion does not elicit suppression of the renin-
angiotensin-aldosterone (RAA) system (8). In contrast, all
of these maneuvers reflexively suppress AVP, plasma renin
activity and the RAA axis in subjects with intact cardiac
innervation. In a previous attempt to evaluate the role of
cyclosporine in fluid retention, we measured plasma volume
(PV) in both HTRs (n 5 11) and in a cyclosporine control
group consisting of age-matched liver transplant recipients
(n 5 6) (2). The HTRs demonstrated moderate PV
expansion (14%), but the liver transplant recipients were
normovolemic, despite receiving equivalent amounts of
cyclosporine. The disparity in extracellular fluid volume
between heart and liver transplant recipients was not ac-
companied by significant differences in either rest left
ventricular or renal function between the two transplant
groups (2).
The purpose of this study was to determine if long-term
extracellular fluid volume expansion in HTRs is caused by
an inability to suppress reflexively the RAA system when
patients become hypervolemic. We speculated that pharma-
cologic suppression of the RAA axis could return HTRs to
a normovolemic state. Accordingly, we employed a cross-
over design and measured PV and fluid-regulatory hor-
mones in HTRs under carefully standardized conditions
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both before and after high dose angiotensin-converting
enzyme (ACE) inhibition with captopril.
METHODS
Subjects. Eight male HTRs (57 6 6 years old) were
entered into the study 22 6 4 months (group mean) after
transplantation. The HTRs were clinically stable and free of
significant rejection, infection or other major illness, and all
received immunosuppressive therapy with cyclosporine,
prednisone and azathioprine. The HTRs were receiving
maintenance doses of prednisone (5 to 10 mg/day) at the
time of the study, and none had required enhanced corti-
costeroid doses within six months of the study. All HTRs
had biatrial anastomosis at transplantation. The HTRs
underwent endomyocardial biopsy within two months of
the study, and there was no evidence of rejection at the time
of biopsy in any of the subjects. The whole-blood cyclo-
sporine trough level, calculated as an average of four
determinations over six months before the study, was 225 6
18 ng/ml (group mean). None of the transplant recipients
were hypertensive before transplantation, but all required
antihypertensive agents for management of hypertension
after transplantation. None of the HTRs had evidence of
cardiac allograft vascular disease.
Study design. This study was a cross-over design per-
formed in the Clinical Research Center (CRC) at Shands
Hospital at the University of Florida. Extracellular fluid
volume and fluid-regulatory hormones were measured in the
same cohort of HTRs under two conditions: visit 1) after
discontinuation of all diuretic and antihypertensive agents;
and visit 2) after a 14-day regimen of ACE inhibition
consisting of a target dose of 225 mg/day of captopril. The
protocol was approved by the Institutional Review Board for
the protection of human subjects at the University of
Florida, and all subjects provided written, informed consent
to participate in the study.
Protocol without captopril. Diuretics and all antihyper-
tensive agents were discontinued 10 days before the study.
No alpha- or beta-blockers or other cardiac medications
were used by the HTRs. The subjects did not add salt to
their usual diet for four days before admission to the
hospital. Thereafter, they were admitted to the CRC. The
first three days in the CRC were an equilibration to the
controlled diet, which consisted of sufficient calories to
maintain the subjects’ current weight and provided 87
mEq/day of Na1 and 80 mEq/day of K1. This diet was
served as three meals taken at 8:00 AM, 12:00 PM and 5:00
PM. Water intake was standardized to 1,000 ml on day 3, but
was provided as desired on all other days of the study.
Consumption of alcohol, caffeine and tobacco products was
not allowed.
Subjects were awakened each morning at 7:00 AM, and
while still supine, blood pressure was recorded in triplicate
using an automated system (Datascope Corp., Paramus,
New Jersey). Blood samples were drawn from an indwelling
venous catheter for analysis of plasma concentrations of
AVP, angiotensin II, aldosterone and atrial natriuretic
peptide (ANP). A 24-h urine collection was started each
morning at 7:00 AM. All subjects were within 15% of Na1
balance before the PV measurements were taken on the
morning of day 4.
On day 4, PV was measured. At 7:00 AM, the subjects
were awakened and blood samples were obtained for deter-
mination of fluid balance hormones and hematocrit; renal
creatinine clearance was also determined. The subjects then
stood and voided and returned to a supine posture. After
60 min of supine rest, the PV measurement was taken (9).
After a 48-h period of observation, diuretic and antihyper-
tensive agents were restarted, and the subjects were dis-
charged from the CRC.
Protocol with captopril. After approximately four months
(group mean 16 6 5 weeks), the same cohort of HTRs (n 5
8) again discontinued all diuretic and antihypertensive
agents. The subjects were then progressed to a captopril
target dose of 75 mg three times per day for 14 days and
were admitted a second time to the CRC. The equilibration
protocol and PV measurements described earlier were re-
peated for each subject.
Blood sample collection. Blood samples for PV measure-
ments were drawn into vacutainers containing heparin.
Blood samples for AVP, angiotensin II, aldosterone and
ANP were drawn into vacutainers containing EDTA.
Plasma was separated by centrifugation at 3,500 3 g at 4°C
for 20 min and the samples were frozen at 280°C until the
assays were performed.
PV analysis. Plasma volume was determined by using a
modified Evans blue dye (T-1824) dilution technique (9).
Plasma samples were drawn at 10, 20 and 30 min after
injection of blue dye, and the data were extrapolated to
zero-time in calculating the PV. The dye from the plasma
samples was extracted onto a wood-cellulose powder (Solka
Floc SW 40A) chromatographic column after it had been
separated from albumin by the action of detergent (Teepol
610 in 2% Na2HPO4). Interfering substances such as
pigments, proteins and chylomicrons were washed from the
column with 2% Na2HPO4. The dye was then eluted from
the column with a 1:1 acetone-water mixture. The addition
of KH2PO4 buffered the pH of the eluate to 7.0; absorbance
of the eluate was read at 615 nm. Duplicate microhemat-
ocrit (Hct) determinations were made using a microhema-
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ANOVA 5 analysis of variance
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tocrit centrifuge (IEC, model MB, Needham Heights,
Massachusetts) and a IEC Micro-Capillary Tube Reader.
Raw Hct values were corrected (30.91) for trapped plasma
and for whole-body Hct (10). Blood volume was calculated
as PV/(1 2 corrected Hct).
Neurohormone analyses. The PV and neurohormone as-
says used in the present study have been used reliably in our
laboratory for numerous experiments in human subjects
(2,3,8,11,12). Plasma AVP was measured by radioimmuno-
assay, as previously described (11). Plasma angiotensin II
and aldosterone levels were determined by radioimmunoas-
say, as previously described by Braith et al. (12). Atrial
natriuretic peptide was extracted from plasma using a
modification of a technique also described by Braith et al.
(8). Plasma (1 ml) was deproteinized by adding 750 ml of
0.1 mol/liter acetic acid and 1.25 ml methanol. The samples
were placed on a rocking shaker for 10 min, followed by
centrifugation for 20 min at 6,000 rpm at 4°C. The
supernatant was dried by vacuum centrifugation. Radioim-
munoassay was performed with a kit from Peninsula Lab-
oratories (Belmont, California) by using ANP antiserum
that has 0% cross-reactivity with human brain natriuretic
peptide and C-type natriuretic peptide.
The Na1 and K1 concentrations in urine and plasma
were measured using a Nova-1 electrolyte analyzer (Nova
Biomedical, Waltham, Massachusetts). Plasma osmolality
was measured with a vapor pressure osmometer (Wescor
Inc., Logan, Utah). Standard methods were used for the
measurement of serum creatinine and the calculation of
creatinine clearance.
Hemodynamic data and left ventricular function. To
evaluate the possible contribution of cardiac function on
fluid volume status, the subjects underwent right heart
catheterization using standard thermodilution techniques
and two-dimensional echocardiography. These examina-
tions were all performed during the interval between the two
CRC admissions.
Statistical analysis. Plasma volume, neurohormone and
creatinine values before and after ACE inhibition were
compared using intragroup analysis of variance (ANOVA),
with only two levels of classification (with and without ACE
inhibition). Plasma volume values in HTRs before ACE
inhibition and, after it, in age-matched healthy control
subjects and in age-matched liver transplant recipients were
compared using ANOVA and the Scheffe´ post-hoc multiple
comparisons procedure. The ANOVAs were performed
using the SAS general linear model procedure (SAS Insti-
tute Inc., Cary, North Carolina). An alpha level of p , 0.05
was required for statistical significance.
RESULTS
Clinical status. There were no changes in clinical status for
any HTR between the two admissions to the CRC. There
were no significant changes in body weight, and the immu-
nosuppression regimen was not changed for any subject
during the study.
Cardiac function. The hemodynamic and left ventricular
function data are presented in Table 1. The mean cardiac
index was 2.80 6 0.53 liters/min per m2, which falls within
the lower one-third of the normal range of 2.4 to 4.2
liters/min per m2 (13). Right atrial mean pressure for the
group was slightly elevated at 6.1 6 1.0 mm Hg, which was
22% greater than the accepted maximal right atrial mean
pressure of 5 mm Hg, whereas the mean occluded pulmo-
nary artery pressure of 10.3 6 3.2 mm Hg fell within the
stated normal range of 2 to 12 mm Hg (13). These
observations are consistent with other investigators’ sugges-
tions that the cardiac allograft exhibits mild or occult
diastolic dysfunction, particularly of the right ventricle
(14,15).
Fluid volume. Blood volume, PV and electrolyte data are
presented in Table 2. Blood volume and PV, normalized for
body weight (ml/kg), were significantly reduced by 12%
when the HTRs were receiving captopril, as compared with
the identical CRC protocol and measurements performed
when HTRs were not receiving captopril. The reduction in
PV observed when HTRs were receiving high dose capto-
pril was not associated with significantly different concen-
trations in plasma Na1 or plasma osmolality.
Renal function. Urine volume and urinary salt excretion
during the 24 h preceding the PV measurements were not
significantly different (p . 0.05) before (0.9 6 0.2 ml/kg per
h; 3.6 6 0.2 mEq/h) versus after captopril (0.8 6 0.3 ml/kg
Table 1. Hemodynamic Data and Left Ventricular Function During Supine Rest in Heart Transplant Recipients (n 5 8)
Patient No.
Mean RAP
(mm Hg)
Mean OPAP
(mm Hg)
CI (liters/min
per m2)
VST
(mm)
PWT
(mm) EF (%)
1 7 18 3.73 8 10 60
2 6 10 3.43 10 11 55
3 10 14 2.48 9 10 60
4 8 8 2.39 11 11 46
5 6 4 3.40 8 9 60
6 6 13 1.90 10 10 58
7 6 8 1.96 9 9 55
8 4 7 3.10 9 10 60
Mean 6 SD 6.1 6 1.0 10.3 6 3.2 2.80 6 0.53 9.2 6 1.0 10.0 6 0.5 57.1 6 3.7
CI 5 cardiac index; EF 5 ejection fraction; OPAP 5 occluded pulmonary artery pressure; PWT 5 posterior (ventricular) wall thickness; RAP 5 right atrial pressure; VST 5
ventricular septal thickness.
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per h; 3.4 6 0.2 mEq/h). Likewise, serum creatinine levels
and 24-h creatinine clearance were not significantly different
before (1.6 6 0.4 mg/dl; 80.0 6 23 ml/min) versus after
captopril (1.5 6 0.5 mg/dl; 82.0 6 19 ml/min).
Fluid-regulatory hormones. The neurohormone data are
also presented in Table 2. Supine angiotensin II and
aldosterone levels were significantly (p , 0.05) greater
before versus after captopril, with levels suppressed by 65%
and 75%, respectively. The changes in AVP and ANP levels
after captopril did not reach statistical significance (p .
0.05). The elevated angiotensin II and aldosterone levels
before captopril, despite PV expansion (12%), suggest that
the RAA axis in HTRs is not suppressed by a hypervolemic
stimulus.
DISCUSSION
Principal findings. Our data confirm previous reports that
extracellular fluid volume is expanded (12%) in HTRs
(1–3,8). The results support the hypothesis that fluid
retention in HTRs is partly engendered by failure to
reflexively suppress the RAA axis when patients become
volume expanded. Pharmacologic suppression of the RAA
axis with high dose captopril (225 mg/day) returned HTRs
to a euvolemic state. This conclusion is strengthened by the
cross-over study design with the same cohort of HTRs
studied before and after high dose ACE inhibition, with
each subject serving as his or her own control, as well as the
standardization of dietary salt, water and caloric intake for
three days before the measurements.
Extracellular fluid volume in health and disease. In an
attempt to interpret the physiologic significance of the
relative reduction in fluid volume in our cohort of HTRs
after captopril administration, we compared the PV levels of
the present study with those levels in two reference groups
previously studied in our laboratory under identical condi-
tions (without captopril): 1) healthy age-matched subjects;
and 2) age-matched liver transplant recipients (Fig. 1). The
regimen of high dose ACE inhibition in HTRs contracted
PV to euvolemic levels that are essentially the same (p .
0.05) as those observed in normal control subjects with
intact cardiac innervation and in orthotopic liver transplant
recipients with intact cardiac innervation who were immu-
nosuppressed with cyclosporine.
Hemodynamic data and left ventricular function. Ab-
normal cardiac allograft systolic function is one possible
alternative explanation for expanded extracellular fluid vol-
ume in HTRs. Although clinical evidence suggests occult
diastolic dysfunction in long-term, clinically stable heart
transplant recipients (14,15), previously published data from
our laboratory (2,3,16), other published data (14,15) and the
hemodynamic data for the subjects of this study all indicate
that cardiac index at rest is maintained within the normal
range, albeit generally toward the lower one-third of the
normal range. The echocardiographic findings in the
present cohort did not indicate abnormal hypertrophy and
confirmed normal left ventricular systolic function (Table
1). Thus, with normal systolic function, the expanded
extracellular fluid volume that we observed in HTRs before
captopril likely cannot be attributed to differences in cardiac
output. However, our hemodynamic and fluid homeostasis
measurements were not simultaneous. Rather, the hemody-
namic assessments in HTRs were performed during the
interval (16 6 5 weeks; group mean 6 SD) between the first
(without captopril) and second (with captopril) fluid balance
measurements, and therefore somewhat limit the generali-
zation of cardiac hemodynamic data to the physiologic state
of the patient at the specific times that fluid volume was
studied.
Cyclosporine and renal function. Cyclosporine-induced
nephrotoxicity, including cyclosporine-mediated increases
in renal vascular resistance and endothelial dysfunction (17),
Figure 1. Plasma volume values in age-matched normal control subjects
(n 5 7) in the same cohort of HTRs (n 5 8) before and after stabilization
on captopril (225 mg/day) and in age-matched liver transplant recipients
(n 5 6). Data are presented as the mean value 6 SEM. *p , 0.05 versus
HTR after captopril, control and liver transplant groups.
Table 2. Fluid Volume, Plasma Electrolytes and Fluid-
Regulatory Hormone Values in Heart Transplant Recipients
(n 5 8) Before and After High Dose Captopril
Before
Captopril
After
Captopril % Change
Plasma volume
(ml/kg)
42.9 6 6 37.6 6 5* 212.3 6 1.3*
Blood volume
(ml/kg)
67.3 6 10.7 58.5 6 8.9* 213.1 6 0.9*
Plasma Na1
(mEq/liter)
141.4 6 1.7 140.1 6 1.5 21.0 6 0.01
Plasma osmolality
(mOsm/liter)
301.5 6 20 300.9 6 16 20.1 6 0.02
Arginine
vasopressin
(pg/ml)
3.7 6 1.2 2.8 6 0.8 224.3 6 9.7
Angiotensin II
(pg/ml)
5.6 6 1.2 1.9 6 0.8* 265.2 6 7.4*
Aldosterone
(pg/ml)
168.0 6 22 41.8 6 10* 275.4 6 9.2*
Atrial natriuretic
peptide (pg/ml)
56.8 6 7 45.5 6 9 219.8 6 6.3
*p , 0.05 before versus after captopril. Data are presented as the mean value 6 SD.
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is another possible explanation for expanded extracellular
fluid volume in HTRs. Indeed, most reports of fluid
retention in organ transplant recipients have emphasized
cyclosporine-induced nephrotoxicity (5,7,17). The adverse
effects of cyclosporine include an increase in renal vascular
resistance and a concomitant decrease in the glomerular
filtration rate and renal blood flow; these effects are clearly
associated with fluid retention. In the present study, we
relied on the semiquantitative estimate of the glomerular
filtration rate by using endogenous creatinine clearance.
Although this technique may not be sufficiently sensitive to
detect small differences in filtration in HTRs before and
after captopril, our data indicate that the glomerular filtra-
tion rate was the same in our cohort of HTRs before and
after high dose ACE inhibition. Our finding of normal
extracellular fluid volume in HTRs after captopril, despite
an unchanged cyclosporine dose and cyclosporine trough
levels, clearly shows that the cyclosporine effect alone is an
inadequate explanation for the fluid volume expansion
detected in HTRs. Rather, our findings suggest that the
moderate fluid retention that we have described in HTRs is
derived from the combination of a deafferented heart (not
allowing us to detect fluid volume expansion and appropri-
ately suppress the RAA axis) and the use of cyclosporine,
which further attenuates the abnormal renal salt and water
handling.
Cardiac denervation and neuroendocrine function. Be-
fore captopril, plasma levels of angiotensin II, aldosterone
and AVP in HTRs were within the normal range for
subjects measured in our laboratory in the recumbent
position. This finding was surprising, however, because the
observed 12% blood volume expansion in HTRs before
captopril could be expected to suppress angiotensin II,
aldosterone and AVP. In various mammalian species, hy-
pervolemia leads promptly to renal vasodilation, diuresis and
natriuresis (18–21). These renal responses are mediated, in
part, by cardiac mechanoreceptors located in atrial and
ventricular chambers, which play a central role in sensing
changes in blood volume (19–21). Normally, innervated
cardiac mechanoreceptors respond to hypervolemia by sup-
pressing AVP, the RAA axis, thirst and sympathetic traffic
to the kidney (19–21). In concert, these compensatory
responses increase diuresis and natriuresis, which return
extracellular fluid volume to the euvoluemic state. Surgical
denervation of cardiac afferent fibers in animal models is
known to attenuate and delay both the diuretic and natri-
uretic response to hypervolemia (22–26).
Clinical relevance. Failure to reflexively suppress the RAA
axis when HTRs become hypervolemic may be responsible,
in part, for the unique severity of de novo post-
transplantation hypertension in some HTRs. In the present
study, we observed a PV increase of 12% when, theoreti-
cally, a fluid volume increase of only 3% to 4% can result in
sustained hypertension (27). In a previous study, we exam-
ined the arterial blood pressure and renal and endocrine
responses to abrupt volume expansion in HTRs (8). Infu-
sion of 0.154 mol/liter saline at 8 ml/kg per h for 4 h elicited
a hypertensive response (15 6 8/8 6 5 mm Hg), which
persisted for 48 h. In addition, saline infusion did not
reflexively suppress AVP, angiotensin II and aldosteone in
HTRs. Net urine flow and urinary Na1 excretion were
blunted and delayed in HTRs, resulting in elimination of
only 51% of the Na1 load over 48 h, which may be caused
by failure to reflexively suppress fluid-regulatory hormones.
These defects in blood pressure and fluid homeostasis were
not seen in age-matched normal control subjects or in liver
transplant recipients who were also immunosuppressed with
cyclosporine (8).
Diuretic therapy may be ineffective at mitigating fluid
retention in HTRs. Previous studies of hydrochlorothiazide
and furosemide therapy for hypertension have shown that
initial decreases in PV, glomerular filtration rate and renal
blood flow return to pretreatment values within 6 to 12
weeks of continuous therapy (28). The first dose of a
diuretic agent increases the urine flow rate and renal Na1
excretion and decreases body weight. However, with re-
peated administration, progressive losses of salt and water
are soon curtailed, and the reduced body weight stabilizes
(29). This “diuretic braking phenomenon” appears to be
independent of the class of diuretic agent given and is
achieved by a combination of renal Na1 retention in the
postdiuretic period and by resistance to the natriuretic
response to the diuretic agent (30).
Study limitations. This study was limited by a small
sample size and the sequential order in which HTRs had
their two in-patient fluid volume studies. However, the
small sample and nonrandomized order of study patients
with and without captopril is compensated by the cross-over
design of the study, wherein each subject served as their own
control.
Conclusions. We demonstrated, in a small cohort of
HTRs, that extracellular fluid volume is expanded (12%) in
HTRs, and that fluid retention is partly engendered by a
failure to suppress the RAA axis when patients become
hypervolemic. Pharmacologic suppression of the RAA axis
with high dose captopril (225 mg/day) returned HTRs to a
euvolemic state. Poor adaptation of the RAA axis to fluid
retention may be partly responsible for the incidence and
severity of post-transplant hypertension in some HTRs.
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